» Articles » PMID: 35488777

Recurrent Copy Number Alterations Involving EGFR, CDKN2A, and CCND1 in Oral Premalignant Lesions

Overview
Specialties Dentistry
Pathology
Date 2022 Apr 30
PMID 35488777
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A major challenge in the management of patients with oral leukoplakia is the difficulty to identify patients at high risk of developing oral squamous cell carcinoma. Our knowledge about genomic alterations in oral leukoplakia, and in particular those that progress to oral squamous cell carcinoma, is scarce and there are no useful biomarkers that can predict the risk of malignant transformation.

Methods: Using a novel, custom-made tissue microarray including 28 high-risk oral leukoplakias and the corresponding oral squamous cell carcinomas from 14 cases that progressed to cancer, we assayed copy number alterations involving the oral squamous cell carcinoma driver genes CDKN2A, CCND1, EGFR, and MYC by fluorescence in situ hybridization. The copy number alterationss were correlated with clinicopathological data from all patients.

Results: Copy number alterations were identified in 14/24 oral leukoplakias, analyzable for one or more of the oral squamous cell carcinoma driver genes. EGFR was the most frequently altered gene in oral leukoplakias with amplification/gain in 43.5% followed by loss of CDKN2A (26.1%), gains of CCND1 (26.1%), and MYC (8.3%). Losses of CDKN2A were more common in oral leukoplakias progressing to oral squamous cell carcinoma compared to those that did not. Copy number alterations were more common in oral squamous cell carcinomas than in oral leukoplakias.

Conclusions: Our findings demonstrate that copy number alterations involving the oral squamous cell carcinoma drivers CDKN2A, EGFR, and CCND1 occur in oral leukoplakias and suggest a possible role for these genes in the development and/or progression of subsets of oral leukoplakias.

Citing Articles

Biomarkers of malignant transformation in oral leukoplakia: from bench to bedside.

Cai X, Zhang J, Zhang H, Li T J Zhejiang Univ Sci B. 2023; 24(10):868-882.

PMID: 37752089 PMC: 10522567. DOI: 10.1631/jzus.B2200589.


Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions.

Jawert F, Fehr A, Ohman J, Stenman G, Kjeller G J Oral Pathol Med. 2022; 51(6):546-552.

PMID: 35488777 PMC: 9546103. DOI: 10.1111/jop.13303.

References
1.
Holmstrup P, Vedtofte P, Reibel J, Stoltze K . Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2005; 42(5):461-74. DOI: 10.1016/j.oraloncology.2005.08.011. View

2.
Lodi G, Porter S . Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med. 2008; 37(2):63-9. DOI: 10.1111/j.1600-0714.2007.00575.x. View

3.
Tsui I, Poh C, Garnis C, Rosin M, Zhang L, Lam W . Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int J Cancer. 2009; 125(9):2219-28. PMC: 2761835. DOI: 10.1002/ijc.24611. View

4.
Benchekroun M, Saintigny P, Thomas S, El-Naggar A, Papadimitrakopoulou V, Ren H . Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010; 3(7):800-9. PMC: 2900459. DOI: 10.1158/1940-6207.CAPR-09-0163. View

5.
A Alaizari N, Sperandio M, Odell E, Peruzzo D, Al-Maweri S . Meta-analysis of the predictive value of DNA aneuploidy in malignant transformation of oral potentially malignant disorders. J Oral Pathol Med. 2017; 47(2):97-103. DOI: 10.1111/jop.12603. View